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In drug discovery, time and resource constraints necessitate increasingly early decision making to accelerate or stop preclinical
programs. Early discovery drug candidates may be potent inhibitors of new targets, but all too often exhibit poor pharmaceutical
or pharmacokinetic properties that limit the in vivo exposure. Low solubility of a drug candidate often leads to poor oral
bioavailability and poor dose linearity. This issue is more signiﬁcant for eﬃcacy and target safety studies where high drug
exposures are desired. When solubility issues are confronted, enabling formulations are often required to improve the exposure.
However, this approach often requires a substantial and lengthy investment to develop the formulation. Previously, we introduced
a gastrointestinal (GI) transit time-based novel oral tandem dosing strategy that enhanced in vivo exposures in rats. In this study,
a reﬁned time interval versus dose theory was tested. The resulting in vivo exposures based on altering frequency and doses were
compared, and signiﬁcant impacts were found.
1.Introduction
In the pharmaceutical industry today, an increasing number
of low solubility drug candidates are providing scientists
with the challenge of reaching desired exposures in vivo.
Novel technologies have been developed for both the clinical
and preclinical drug delivery of poorly soluble molecules
[1, 2]. The pharmaceutical industry has increasingly pushed
towards a programmatic “fail fast/fail cheap” paradigm in an
eﬀort to reduce costs and allocate resources in an eﬃcient
manner [3]. For a research program, early assessment of the
eﬃcacy and safety is often dependent upon eﬃcient drug
administration to generate reliable in vivo results in animal
models for a “go” or “no go” decision. However, early drug
candidates often exhibit poor pharmacokinetic attributes
and physicochemical properties, such as poor solubility,
making in vivo activity assessment diﬃcult due to low expo-
sure. Formulation-based approaches to improve exposure
of these compounds, such as the addition of organic co-
solvents, cyclodextrin, or emulsions, are most commonly
used. However, the above approaches may interfere with
the pharmacodynamic readout of the in vivo model or
may not be tolerated by the subjects if multiple dosing
is required to reach sustained systemic levels [4, 5]. Such
issues become more problematic when early lead candidates
are used for target safety evaluation where no interference
from the vehicle formulation is allowed. Delivery options
such as the use of biomaterials and polymeric delivery
systems have been developed to address these issues [6, 7].
However, these tools are often costly and require a large
amount of drug which makes them more suitable to be
applied in a drug development environment. Other delivery
technologies such as nano- and microparticle drug delivery
systems have been applied throughout the pharmaceutical
industry. These systems have mainly focused on oral,
intraperitoneal, intramuscular, or subcutaneous delivery [8–
10]. Theoretically, particle size reduction only improves
dissolution by increasing surface area as described by Noye-
Whitney, and marginally improves solubility as describe by
Oswald-Freundlich[11].Unfortunately,theseimprovements
often fall short to overcome the solubility limited absorption
when the dose is increased. Frequently, when solubility limit2 Journal of Drug Delivery
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Figure 1: Tandem dose scheme.
absorption is encountered, researchers have no choice but
to wait for a more suitable drug candidate which often
results in delay and increased cost. In many cases, higher
doses (i.e., 1000 to 2000mg/kg) are used in vivo in a futile
attempt to increase exposure. This only wastes time and
drug without answering the critical questions. In some
cases where the linear absorption range of a drug can be
found, b.i.d. (twice a day, every 12 hours) or t.i.d. (three
times a day, every 8 hours), doses are used to increase
exposure in model animals. However, these approaches often
require signiﬁcant staﬃng investments (late night shifts)
whicharenotwelcome.Moreover,foracompoundwithhigh
clearance, drug accumulation after b.i.d. or t.i.d. dosing will
belesssigniﬁcant.Suchadosingregimenwillresultinhigher
exposure (AUC) but with no Cmax increase, which is usually
strongly desired.
In our previous study, an eﬀective tandem dose delivery
method was successfully established [12]. This novel dose
strategy is based on animal anatomy and biological rhythms.
The theory was focused on utilizing animal gastrointestinal
(GI) transit time and considered the gastrointestinal track
to be a multicompartment system. In a one-direction
multicompartment GI model as illustrated in Figure 1, the
stomach and small intestine (duodenum, jejunum, and
ileum) were considered to be the major compartments of the
system and each compartment was considered to be acting
as an individual unit. In this model, when drug is dosed, the
excretion from stomach to small intestine is considered to
start immediately. The geometric center of the un-dissolved
drug mass moves along from compartment to compartment
and eventually reaches the large intestine. Little absorption
takes place in the large intestine, and so it is not considered
an active compartment in this model. The model is based
on treating the drug mass as one band, and the geometric
center of that band is located at the point of the highest
density of un-dissolved drug. Once the geometric center
of the dose passes through a compartment, the previous
compartment is considered empty and ready for another
round of drug. If we utilize this compartment again as soon
as it becomes available and space the doses correctly, we
should be able to use a more frequent dose in a short time
frame thus approximating “oral infusion.” Several researches
have reported the GI transit time of small lab animals [13–
22]. Based on those reported values and in-house data, the
GI transit time for a rat is anywhere from 2.5hrs to 12hrs.
T h ep r e v i o u s l yt a n d e md o s ew o r kw eh a v ed o n eu s e daﬁ x e d
dose interval of2.5hrsas astarting interval totest thetheory.
It is believed that an interval of two to three hours should
be suﬃcient to separate two doses from each compartment.
Thus, an absorbable amount of drug can be dosed every two
to three hours as a tandem dose without having signiﬁcant
0
5
10
15
20
25
0 200 400 600 800 1000 1200 1400
(minutes)
Simulation fort.i.d.
Simulation fortandem dose
(
µ
M
)
Figure 2: PK simulation of tandem versus regular t.i.d. dose.
dose overlap. This tandem dose approach provided several
advantages compared with regular b.i.d. or t.i.d. doses. First,
this approach eliminates the need for overtime and late night
shifts. Second, unlike regular b.i.d. or t.i.d. doses that often
only improve AUC for drugs with higher clearance, this
approach allows for continuous absorption of drug. This
allowsthedrugconcentrationinplasmatobuildupviaaccu-
mulation, resulting in a much higher Cmax w h i c hi sc r i t i c a l
for target proof of concept (POC) and safety evaluation.
The impact on AUC and Cmax of a hypothetical com-
poundbya3Xtandemdosewitha2.5hrsintervalversusthat
of a t.i.d. dose is illustrated in Figure 2.T h eP Kp a r a m e t e r s
used for the hypothetical compound are representative of
several internal preclinical candidates. The compound is
assumedtohave anoralbioavailability of 30%with avolume
of distribution (Vd) of 1L/Kg and medium clearance (CL)
in rat of 20ml/min/Kg. A previously established in-house
oral model based on the Bateman equation was used for
the simulation [12] .T h i sa p p r o a c hh a sb e e np r o v e nt ob e
very eﬀective in the preclinical setting. We have demon-
strated that with this oral tandem dose, higher exposures
(Cmax and AUC) are achievable without employing enabling
formulations and while conserving the amount of active
pharmaceutical ingredient required [12]. Most importantly,
no extra staﬃng resources were needed.
Despite the success of this GI transit time-based tandem
dosing strategy, one question remained. The optimum
tandem dose interval had yet to be fully studied. A ﬁxed
2.5hrs dosing interval was used in the previous study and
successfully demonstrated the theory. However, in order
to take full advantage of this novel strategy, a better
understanding of dose versus interval was needed. In both
studies, a low solubility compound was tested with tandem
dose. Compound 1 is a potent phosphodiesterase 2 (PDE2)Journal of Drug Delivery 3
inhibitor. PDE2 is one of the most important downstream
targets of phosphodiesterase. It has been reported that
inhibition of PDE2 will result in the regulation of cyclic
guanosine monophosphate (cGMP) signaling and may aﬀect
anxiety-related behavior through reduction of oxidative
stress [23–26]. This compound was found to have good
potency with an IC50 value of less than 5nM in the in vitro
assay and good permeability by Caco-2 assay. However, the
physical properties of the free form of Compound 1 were
not suited for dose escalation to deliver the desired exposure.
Compound 1 was highly crystalline, and the solubility of
the crystalline free base was approximately 10μMi np H6 . 5
buﬀer. This suggested that at higher doses, oral absorption
of Compound 1 would most likely be solubility limited (BCS
class II).
Based on the earlier single-dose exposure data, the
upper limit of the linear dose range of Compound 1 was
found to be 300mg/Kg [12] .Am u c hi m p r o v e de x p o s u r e
(compared with s.i.d.) was observed when compound 1
was tandem dosed using an interval of 2.5hrs. In this
study, we further compared the impact on exposures by
altering both dose amount and dose interval. Our data
demonstrates that optimizing dosing interval based on dose
amount can signiﬁcantly increase in vivo exposure. Our
eﬀort has demonstrated the validity and practicality of the
novel tandem dose for preclinical drug delivery.
2.MaterialsandMethods
2.1. Materials. HPLC grade acetonitrile was obtained from
Burdick & Jackson (Muskegon, MI) and reagent grade
formic acid, sodium hydroxide obtained from EM Science
(Gibbstown, NJ). The HPLC system used was an Agilent
HP 1100 HPLC equipped with a diode array (DAD), a
variable wavelength UV (VWD) detector, and a quaternary
solvent delivery system (Palo Alto, CA). The LC/MS system
used a Shimadzu solvent delivery system and a CTC PAL
autosampler combined with a SCIEX 4000 tandem mass
spectrometer from Applied Biosystems (Foster City, CA). A
Zorbax SB-C8 column (5μm, 4.6∗150mm) was selected
and used for HPLC analysis, and a Thermosil Aquasil C18
column (3.5μm, 2.1∗50mm) was used for LC/MS. For
HPLC analysis, the water puriﬁcation system used was a
Millipore milli-Q system. For LC/MS, HPLC grade water
from EMD Scientiﬁc, Inc. was used.
Powder X-ray diﬀraction (PXRD) was done on either a
BrukerD-8AdvancediﬀractometeroraBrukerD-8Discover
with GADDS diﬀr a c t o m e t e r .I nb o t hc a s e s ,C uk ar a d i a t i o n
was employed. For the D-8 Advanced, in-house fabricated
aluminum inserts or inserts with a Hasteloy sintered ﬁlter
(0.45μm) pressed in the center and held in Bruker plastic
sample cup holders were utilized for all analyses. A Beckman
Coulter (Miami, FL) LS 230 particle size analyzer using the
small volume accessory was employed for analyzing particle
size. Particle size distribution was computed by the software
using Mie scattering theory, and a PIDS obscuration water
optical model was employed.
Compound 1 was prepared at Pﬁzer, and materials used
forallinvitroandinvivostudieswerefromthesameprepara-
tion. All other chemicals were obtained from Sigma-Aldrich
(St. Louis, MO) and were used without further puriﬁcation.
2.2. Solubility, Solid-State Properties, and Formulation Eval-
uation of the Free Base. The solubility of Compound 1 was
assessed by stirring a small amount of crystalline free base in
scintillation vials that contained 5mL of various pH buﬀers
and FASSIF (fasted state simulated intestinal ﬂuid). Samples
were checked periodically to ensure that they were saturated
with excess solid. At the end of 48hrs, a ﬁnal pH reading
was taken for each sample and a representative amount
of the slurry was aliquoted into centrifuge tubes. These
were centrifuged at 14,000rpm for a period of two hours.
Supernatants were transferred into individual HPLC vials,
and the concentration was determined by HPLC (DAD). The
remaining solid form was analyzed by PXRD. Formulations
with aqueous media were prepared by suspending bulk
drug in a vehicle containing 0.5% Methylcellulose and 0.1%
Tween80indistilledwater.Formulationconcentrationswere
adjusted to dose with a ﬁxed dosing volume for all doses
(total dose 20mL/Kg/day). Particle size distribution of each
f o r m u l a t i o nw a sd e t e r m i n e do naB e c k m a nC o u l t e rL S2 3 0
particle size analyzer.
2.2.1. In Vivo Methodology. For in vivo work, male Sprague-
Dawley (SD) rats were purchased from Charles River
Laboratories (Wilmington, MA). This animal study was
approved by the St. Louis Pﬁzer Institutional Animal Care
and Use Committee. The animal care and use program
is fully accredited by the Association for Assessment and
Accreditation of Laboratory Animal Care, International. All
oral doses other than standard Pharmacokinetic studies
were performed under “fed” condition to better estimate
the multiday toxicology study. The oral dose volume was
based on 20mL/Kg/day of body weight for all studies. All
doses were based on mg/Kg of body weight. Rats were
catheterized in the jugular vein and carotid artery for iv
dosingandsampling,respectively.Ateachtimepoint,150uL
of blood was withdrawn from each animal, and replaced
by saline. Blood sampling was carried out using a Culex
Automated Blood Sampling System (West Lafayette, IN)
and collected in microtainer plasma separator tubes with
lithium heparin using heparinized capillary tubes. Plasma
samples were obtained by centrifugation at 8000rpm for
10 minutes, and 20μL of the plasma sample was extracted
with180μLofacetonitrilecontaining0.25μMoftheinternal
standard (prepared in house). The precipitated samples were
centrifuged, and supernatant was transferred to a 96-well
plate. Analytical standards were prepared by spiking known
amount of standards into control plasma and followed the
above extraction procedure. Tandem dosing (three times)
was performed at 50, 100, and 200mg/kg and dose intervals
were 1, 1.5, and 2.5hrs.
Plasma samples were analyzed by LC/MS/MS. A Shi-
madzu LC (LC 20 AD) multiple solvent pump system was
used for the gradient elution. A CTC Pal autosampler was
used for sample injection. Solvent line A contained HPLC
grade water with 0.1% formic acid (v/v), and Solvent line B4 Journal of Drug Delivery
contained acetonitrile with 0.1% formic acid (v/v). The ﬂow
rate was set at 0.4mL/minute, and a Thermo Aquasil C18
20 × 2.1mm, 3.5 micron column was used for analysis. At
T(0), the mobile phase (90% A and 10% B) was mixed by
the HPLC pump and held for 0.5 minutes (isocratic elution).
From T(0.5) to T(1.5) minutes, a linear gradient from 10%
B to 90% B was applied and allowed to hold at 90% B for
1 minute (from 1.5 to 2.5 minutes). At T (2.7) minutes,
the system was set back to the initial condition allowed to
equilibrate for 1.3 minute to prepare for the next injection.
The analyte was quantiﬁed versus a plasma standard curve
using a Sciex API 4000 mass spectrometer with an internal
standard. For the analysis, positive electrospray mode was
used. For sample preparation in general, 20μL plasma was
extracted with 180μL acetonitrile containing 0.25μM of the
internal standard carbamazepine.
2.2.2. Modeling. Pharmacokinetic analysis was performed
using Watson 7.2 Bioanalytical LIMS system by Thermo
Electron Corporation (Thermo Fisher Scientiﬁc, Waltham,
MA). An in-house model based on the Bateman equation
was used for the simulation
Cp(t) =

Ka∗F∗Dpo∗

e−Kt −e−Kat
V(Ka−K)
. (1)
Cp(t): plasma concentration as a function of time. Ka:
absorption rate constant. K: elimination rate constant. F:
bioavailability. Dpo:d o s e( o r a l ) .V: volume of distribution.
t:t i m e
The Wagner-Nelson equation was used to calculate drug
absorbed to further assess the absorption as a function of
time.
dA = V∗dCp + V∗k∗Cp∗dt,
A = V∗Cp + V∗K∗
 t
0
Cp∗dt,
(2)
whereA = drug absorbed. V = volume of distribution. Cp =
plasma concentration. K = elimination rate constant. t =
time. Fraction absorbed = (BA ∗ Hepatic Blood Flow)/(Hepa-
ticBloodFlow-Clearance).RatHepaticBloodFlowis ∼70mL/
min/kg. Absorption rate constant Ka = 1/((MRT)po −
(MRT)iv)). T1/2abs = ln2/Ka.
3. Results andDiscussions
Basic pharmacokinetic parameters of Compound 1 were
obtained from low dose IV (1mg/Kg) and oral (3mg/Kg)
e x p e r i m e n t si nr a t s( n = 3). Compound 1 was found to have
medium CL, a Vd of 6L/kg, and an oral bioavailability of
60%. The absorption constants (Ka) for both compounds
were calculatedusing the mean resident time (MRT)method
by assuming the absorption of Compound 1 followed the
single ﬁrst-order kinetic process [27]. The absorption half-
life was calculated to be approximately 0.87hr for Com-
pound 1. Additional PK and physicochemical information
of Compound 1 is listed in Table 1. The fraction absorbed
was calculated by assuming that CL was mainly hepatic. The
Table 1:BasicPKandphysicochemical parameters ofcompound1.
Parameters Compound 1
Ka(−1/hr) 0.8
CL (mL/min/kg) 22
Vdss (L/kg) 6.0
T1/2 (Hrs) 6.9
MRT Oral (3 mg/kg)/IV (1mg/kg) 6.1/4.8 (hrs)
Oral BA (3mg/kg) 60%
Aqueous solubility (pH 6.5) 10μM
Solubility in FASSIF 15μM
pKa (between pH 2 and 10) None
LogD (pH 7.4) 3.0
fraction absorbed (FA) was calculated to be approximately
0.79.
For Compound 1, oral absorption was not an issue when
doses were low. However, good FA at low doses does not
always translate to good FA when the dose is increased.
Given the low solubility of the compound, solubility limited
absorption is still likely to occur at higher doses (BCS II).
T h i sp r e s e n t e dam a j o rh u r d l ea sC o m p o u n d1a d v a n c e d
to safety studies where high exposures (both Cmax and
AUC) were needed. In the ﬁrst single dose range ﬁnding
safety study, Compound 1 was dosed in rats as suspension
formulations. Compound 1 was dosed once a day (s.i.d.)
at 300, 600, and 1000mg/kg in rats. Nondose proportional
AUC and Cmax increases were observed (see Table 2).The
exposure increase between 300mg/Kg and 600mg/Kg doses
was small. A two-fold dose increase only resulted in a
0.2 times increase in AUC and a 0.39 times increase in
Cmax. Even smaller increments were found when comparing
exposures between the 600mg/Kg dose and 1000mg/Kg
dose. Exposure (especially the Cmax) was not high enough to
establish appropriate margins to assess the safety liabilities.
The exposures for Compound I reached a plateau at high
doses. As compound 1 possesses low aqueous solubility, it
was hypothesized that for Compound 1, absorption was
limited by solubility at high dose. Formulation options
were evaluated for Compound 1 in order to improve the
exposure. In vitro data (not included) led us to believe that
improving exposure suﬃciently via formulation would be
time consuming, expensive, and therefore not an option.
Regular multidoses b.i.d. (every 12hrs) or t.i.d. (every 8hrs)
were considered and found less favorable since increased
staﬃng and overtime pay (for late night dosing) would be
required. Upon close examination of the data, Compound
1 exhibits nondose dependent exposure increases at higher
doses. However, it is entirely possible that oral absorption
may be linear at doses below the lowest dose (300mg/Kg).
Based on this assumption, we hypothesized that if each
dose is less than 300mg/Kg and administered in a tandem
dose scheme, the high FA (for each dose) and short dose
frequency (every 2.5hrs) would allow drug exposure to
build up very quickly (both AUC and Cmax). The 2.5hrs
dose interval was chosen to test at ﬁrst [12]. The 2.5hrs
interval was picked based on the literature reviews [12–22]Journal of Drug Delivery 5
Table 2: Exposure of compound 2 from s.i.d. dose.
Dose (mg/kg) (N ≥ 3) Frequency Cmax (μM) AUC (μM∗hr) AUC/Dose ± SD (μM∗hr/mg/kg)
300 Once a day 10.6 ±2.8 167 ±36 0.565 ±0.120
600 Once a day 12.9 ±1.2 232 ±29 0.387 ±0.049
1000 Once a day 14.4 ±2.2 273 ±66 0.273 ±0.066
Table 3: Detailed tandem dose scheme and grouping (n ≥ 3 for each group).
Dose (mg/Kg) Frequency/total dose 1hr interval 1.5hrs interval 2.5hrs interval
50mg/Kg X3 tandem (150mg/Kg) Group 1 Group 2 Group 3
100mg/Kg X3 tandem (300mg/Kg) Group 4 Group 5 Group 6
200mg/Kg X3 tandem (600mg/Kg) Group 7 Group 8 Group 9
Table 4: Tandem dose scheme AUC comparison (μM∗hr).
Dose (mg/Kg)/Interval (hrs) 1hr 1.5hr 2.5hr
50 (mg/Kg) X3/AUC/Dose 85 ±41 159 ±69 147 ±31
100 (mg/Kg) X3 192 ±58 289 ±55 310 ±14
200 (mg/Kg) X3 210 ±26 330 ±90 521 ±47
and in house data (not included). This dose interval has
successfully demonstrated to be suﬃcient to separate two
doses (represented by the geometric mean of the unabsorbed
drug at the moment) from each compartment [12]. In
general, rats were dosed at 7 o’clock in the morning (ﬁrst
dose), nine thirty (second dose), and twelve o’clock (third
dose). The exposure results obtained from the tandem dose
were very encouraging. In general, much higher Cmax and
AUC were obtained by the tandem dose compared with the
s.i.d. dose. The 100mg/Kg tandem dose (300mg/kg total)
gave an AUC and Cmax similar to the 1000mg/Kg s.i.d. dose.
The 200mg/Kg tandem dose (600mg/kg total) resulted in
double the exposure of the 1000mg/Kg s.i.d. dose. Most
importantly, the Cmax increase was observed as predicted.
Thus, the utility of this novel tandem dose method has
been demonstrated by lowering the total drug requirement
and still achieving signiﬁcantly improved exposures for
low solubility compounds [12]. A pharmacokinetic model
was established in house by using the Bateman equation
(assuminglinearpharmacokinetics)toestimatetheexposure
from a tandem dosing scheme with success [12].
Despite the success of the tandem dose approach, one
key question remained: what is the optimum dose interval
for a given dose? It is understood that when dose increases,
so does the amount of drug remaining in the GI The risk
of drug “overlap” in the GI may increase when the tandem
dose interval is shortened. When this “overlapped” portion
becomes signiﬁcant, the fraction of nonabsorbable drug will
increase and result in lower exposure even for a tandem dose
(similar to high s.i.d. dose). Vice versa, when a lower dose
is given, the amount of drug remaining in the GI is reduced
and drug overlap from a tandem dose scheme (i.e., 2.5hrs
intervals) is less likely. Thus, a shorter interval could be
used and may provide better eﬃciency. For this study, three
diﬀerent dose levels (50, 100, and 200mg/Kg X3 tandem)
Table 5: Tandem dose scheme average Cmax comparison (μM).
Dose (mg/Kg)/Interval (hrs) 1hr 1.5hr 2.5hr
50mg/Kg X3 7.2 ±2.01 0 .8 ±4.91 1 .1 ±1.6
100mg/Kg X3 11.1 ±2.11 4 .7 ±2.51 5 .9 ±0.4
200mg/Kg X3 12.0 ±0.41 7 .0 ±3.72 6 .3 ±4.0
were used alone with three diﬀerent dose intervals (1, 1.5,
and 2.5hrs). A detailed dose scheme is listed as Table 3.T h e
overall goal is to further study and optimize the tandem
dosing scheme.
All doses were successful and well tolerated by the
animals. For the 50mg/Kg X3 tandem dose, the best
eﬃciency was found when the 1.5 and 2.5hr intervals were
used. The higher Cmax and AUC obtained via the tandem
doses were well within our model prediction (an example
is presented as Figure 3). The exposures obtained by this
50mg/Kg X3 tandem dose are comparable to 300mg/kg
s.i.d dose, and only half the amount of drug was used. The
shortest interval (1hr) was found to be the least eﬀective
and delivered the lowest Cmax a n dA U C ;h o w e v e r ,i tw a s
still respectable. It is hypothesized that with such a short
interval, drug “overlapped” from dose to dose, increasing the
nonabsorbable portion and thereby reducing the exposure
(similar to that of an s.i.d. dose). Better drug delivery
eﬃciency was achieved when the dose interval was increased
to 1.5 and 2.5hrs. Cmax and AUC from both dosing schemes
were comparable. This suggests that for this (low) dose,
1.5hrs was suﬃcient to physically separate the doses in
the GI Exposure proﬁles of the 50mg/Kg tandem dose are
presentedin Figure 3.Theeﬀectsoftandemdosing werevery
clear when comparing the absorption phases (α phase) of
the three dosing curves (Figure 4). With all three intervals,
the absorption phases (rate of uptake) were very similar
and the AUC/Dose (for 1.5hr interval) was calculated to be
1.06 ± 0.46μM∗hr/mg/kg. The eﬀect of the tandem dose
is made evident by the longer absorption phase generated
by both the 1.5 and 2.5hrs dosing intervals. The Wagner-
Nelson equation (see Section 2) was used to calculate the
drugabsorbedandfurtherassesstheabsorptionasafunction
of time. According to the calculation, the δA/δT value for
all three dosing schemes was approximately 2mg/hr. The6 Journal of Drug Delivery
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Figure 3: Compound 1 50mg/Kg X3 tandem dose (2.5hr interval)
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Figure 4: Compound 1 50mg/Kg X3 tandem dose (1, 1.5, and
2.5hrs interval) exposure comparison.
higher exposures observed from the longer dosing interval
were attributed to the increased absorption time (Figure 5).
For the 100mg/Kg tandem dosing groups, similar
impacts were observed when the dose interval changed. In
general, the shortest dosing interval (1hr) gave the lowest
exposures. Again, it is hypothesized with such a short
interval, drug “overlapped” from dose to dose which caused
the nonabsorbable portion to increase thereby reducing the
exposure (similar to an s.i.d. dose). Better drug delivery
eﬃciency was achieved when the dose interval increased
to 1.5 and 2.5hrs. The Cmax and AUC (Tables 4 and 5)
obtained from both dosing schemes are comparable and well
exceed the values from the s.i.d. dose (Table 2 300mg/kg).
This suggests that for this dose (100mg/Kg X3) 1.5hrs
may be suﬃcient to separate two doses as well. However,
it is worth noticing that the variability of data obtained
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Figure 5: The 50mg/kg X3 Tandem Dose Wagner-Nelson Plot
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from the 1.5hr interval is higher than that of the 2.5hr
interval. This suggests that the 1.5hr interval may not be
ideal for higher doses as the risk of drug overlap in the GI is
higher and may have contributed to the higher variability in
exposures. The simulated exposure (2.5hrs interval) versus
the obtained exposure for the 100mg/kg X3 tandem dose is
presented in Figure 6, and the AUC/Dose (for 2.5hr interval)
was calculated to be 1.03±0.05 μM∗hr/mg/kg. Based on
the linear model and exposures obtained from the 1.5 and
2.5hr intervals, a noticeably increased beta phase half-life
was observed from the tandem doses versus the predicted
curve. It is possible that via accumulation the drug exposure
has reached the nonlinear range (saturated the CL), and
therefore a linear PK model underpredicts the beta phase
half-life. A Wagner-Nelson plot (see Section 2)w a su s e dt o
calculate drug absorbed and to assess the absorption as aJournal of Drug Delivery 7
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Figure 7: The 100mg/kg X3 Tandem Dose Wagner-Nelson Plot
(presented as mean values).
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Figure 8: The 200mg/kg X3 Tandem dose predicted (2.5hr) versus
obtained exposures from 1, 1.5, and 2.5hrs interval.
function of time and is presented as Figure 7. Again, the
higher exposures observed from the longer dosing interval
were attributed to increased absorption time.
For the 200mg/Kg tandem dosing groups, a much bigger
impact was observed when dose interval changed. In general,
the shortest dosing interval (1hr) gave the lowest exposure
followed by the 1.5hr interval. Again, it is hypothesized
that with such a short interval, drug “overlapped” from
dose to dose which caused the nonabsorbable portion to
increase thereby reducing the exposure (similar to a s.i.d.
dose). Better eﬃciency was achieved when the dose interval
increased to 2.5hrs. Better drug delivery eﬃciency was
achieved when the dose interval increased to 1.5 and 2.5hrs.
This is not surprising, since for a low solubility drug, the
nonabsorbable portion increases when the dose increases
due to solubility limited absorption. It is also understood
that the dose interval should be Tmax (from single dose)
dependent. The overlap from the shorter dosing interval
becomes more signiﬁcant and the nonabsorbable portion
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Figure 9: The 200mg/kg X3 Tandem Dose Wagner-Nelson Plot
(presented as mean values).
increases as dose increases; thus, the dosing interval and the
dose are interdependent, and both must be considered in
order to minimize the “drug overlap” in the GI track. The
Cmax and AUC (Tables 4 and 5) obtained from the 1.5hrs
dosing scheme are comparable to the values obtained from
the s.i.d. dose (Table 2. 1000mg/kg). Cmax and AUC from
the 2.5hrs dosing scheme well exceed the values obtained
from the s.i.d. dose of 1000mg/kg. The obtained Cmax of
200mg/kg tandem dose (with 2.5hr interval) was 26.3 ±
4.0μM, and AUC/Dose (for 2.5hr interval) was calculated
to be 0.87 ± 0.08μM∗hr/mg/kg. This suggests that for this
dose (100mg/Kg X3) 1.5hrs may be suﬃcient to separate
two doses; however, the 2.5hr interval delivers the best
results. Similarly, the data obtained from the 1.5hr interval
exhibits higher variability when compared to the 2.5hr
interval. This again suggests that 1.5hrs may not be the
ideal interval for higher doses as the risk of drug overlap in
the GI is higher and may contribute to higher variability in
exposures. The variability could also be subject dependent.
The simulated exposure (2.5hrs interval) versus obtained
exposure for 200mg/kg X3 tandem dose is presented in
Figure 8. A Wagner-Nelson plot (see Section 2)w a su s e dt o
calculate drug absorbed and to assess the absorption as a
function of time for the 200mg/kg X3 dose is presented
as Figure 9. Similarly, a noticeable increase in beta phase
half-life was observed for the tandem doses versus the
predicted curve using our linear PK model. It is possible that
via accumulation drug exposure has reached the nonlinear
range (saturated the CL), and therefore a linear PK model
underpredicts the beta phase half-life. It is also possible
that this phenomena was due to the larger amount of drug
dosed which altered some physiological factor (i.e., transit
time) in the animal or saturated the absorption. Thus, the
parameters generated by simple PK studies at a lower dose
may not be suﬃcient to predict every aspect of a higher dose
study. However, since both AUC and Cmax were actually well
within our target, we believed this model work well. It is also
hypothesized that when other factors are kept constant and
compound solubility is improved, the shorter interval may
work better. Better solubility will allow for faster absorption8 Journal of Drug Delivery
of drug, less will remain in the GI, and drug overlap will no
longer be an issue.
The above data strongly support the tandem dose
approach to increase exposure while minimizing compound
usage. The present work supports the transit time theory
in rats. We have also demonstrated that the ideal interval
is dose dependent. In summary, signiﬁcantly improved
exposures were obtained by using the tandem dose with the
appropriate interval. A simple calculation of dose eﬃciency
was performed based on using 40% less drug (600mg/kg
versus 1000mg/kg) and doubling the exposure. This tandem
dose has improved the dose eﬃciency by approximately
300% for Compound 1. This conservative calculation was
done by assuming a linear increase of both Cmax and AUC
from 1000 to 2000mg/Kg doses for both compounds. This
assumption is an overestimation since exposure increases
of Compound 1 (s.i.d) were proven nonlinear beyond
300mg/Kg (and the actual nonlinear dose could be lower
than 300mg/Kg). Thus, the true eﬃciency could be much
higher. This novel tandem dose oral delivery approach using
an optimized dosing interval achieves signiﬁcantly higher
in vivo exposure using less drug and requires no additional
resources. It is simple, cost eﬀective, and well tolerated by
animals and should be further utilized in industry. Regular
b.i.d. or t.i.d. doses take up to 12 or 16 hours to administer.
Depending on the dose, a simple X3 tandem dose can be
administered within 2–5hrs (1 to 2.5hr interval). This easily
ﬁts into the traditional work day, and no additional staﬀ
or overtime is necessary. In theory, the tandem dose is not
limited to three doses per day; a fourth dose can be given
to further boost the exposure if needed without altering the
normal eight-hour work day [12]. Our current investigation
of dosing interval further reﬁnes the tandem dosing strategy.
This improved strategy can positively impact the preclinical
oral delivery of low solubility compounds.
4. Conclusion
In our research, we utilized this novel tandem dose strategy
in rat and assessed the impact of dosing intervals on
exposure. We successfully demonstrated that by using the
tandem dose strategy with the appropriate dosing interval,
signiﬁcantly higher in vivo exposure can be reached without
extraresources and investments. This method is well toler-
ated by the animal and achieves increased exposure with
less drugs dosed. This novel approach allows the preclinical
researchertoquicklyevaluatetheinvivoeﬃcacyandsafetyof
a new target. We believe that by using an approach similar to
the system described above, reliable data for decision making
can be obtained earlier in the discovery process prior to the
need for substantial investments.
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